Alliances and Partnerships, Business, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with Innobiochips to Develop Personalized Diagnostics for Post-Transplant Monitoring and Early Detection of Transplant Rejection

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Innobiochips (IBC), a developer of innovative immunoassays and the SirYus™ diagnostic platform technology, to develop personalized HLA diagnostics that will detect and quantify donor specific antibodies (DSA's) in post-transplant settings and provide the basis for post-transplant monitoring and early detections of transplant rejection.

The research is being led by Innobiochips co-founders Drs. Vianney Souplet and Christophe Olivier, and Dr. Rico Buchli, VP of Products and Services at PTS. The collaboration aims to develop and validate new individualized, allele specific HLA-antibody diagnostics. The initial goals of the collaboration are to quickly develop the first commercial prototype and gather the data needed to validate the platform with leading community experts. The companies are optimistic that they will be able to rapidly provide a new portfolio of allele specific diagnostics to HLA lab directors, transplant clinicians and transplant patients that do not currently exist. These new diagnostics would enable personalized, easy to use, and quantifiable sequential monitoring of patient specific DSA levels, the result of which would provide a new pro-active window for clinicians to implement earlier graft saving interventions for transplant recipients.

"Between our two companies, we feel that we already have the ingredients needed to provide a new set of tools to those who care for transplant patients," Dr. Buchli stated. "Our proteins solve a number of important challenges on the serological side while the Innobiochips SirYus platform provides a very easy to use and elegant way to manufacture discrete, allele specific tests with the necessary controls, it really is a powerful combination."

"Over the past years, our companies have been exploring ways to combine our complementary technologies to create breakthrough diagnostics in the transplant market. PTS has the in-depth knowledge in HLA proteins and IBC has demonstrated that its technology is incredibly flexible and can enable as many as 144 serological assays at the same time in a single well, providing the transplantation departments an outstanding and new solution for HLA detection," Dr Souplet stated.

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation.

Learn more: https://www.puretransplant.com/

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, www.hlaprotein.com, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About Innobiochips

Innobiochips is a diagnostic company committed to provide innovative multiplex immunoassays and aims to position its technology, SirYus™, as a new standard for In Vitro Diagnostics. As of today, Innobiochips has developed and produces products dedicated to transplantation and immunodeficiency and is partnering with several major players to incorporate the SirYus technology into larger IVD applications.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with Northwestern University to Develop Novel Reagents for Enhanced Characterization of HLA DQ Antigens in Transplant Rejection

AUSTIN, Texas -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with Northwestern University, a world leader in HLA DQ antigen research.

The focus of the collaboration is to develop and test novel HLA reagents created by PTS that may be used for enhanced analysis and characterization of DQ antigens, an HLA Class II type that is increasingly gaining importance in causing rejection in transplant patients.

The research is being led by Dr. Anat Tambur, Director of the Transplant Immunology Laboratory and Comprehensive Transplant Center at Northwestern University Feinberg School of Medicine, and Dr. Rico Buchli, VP of Products and Services at PTS.

"The Tambur lab at the Comprehensive Transplant Center, Northwestern University, Chicago, is focusing on understanding the immunogenicity of HLA-DQ antigens and its role in antibody-mediated rejection in solid organ transplantation," said Dr. Tambur. "Increasing evidence has demonstrated that DQ mismatches between transplant recipient and donor are the most common to induce de novo donor-specific antibodies (DSA). HLA-DQ antibodies are likely also the most detrimental to graft survival. Understanding the unique structural and molecular properties that make the HLA-DQ molecule so pathogenic may eventually help us better predict which mismatches will induce harmful antibody formation, and which are more permissible. This work requires availability of purified HLA-DQ and other HLA class II molecules, maintaining high physiologic accuracy of the three-dimensional structure. Our collaboration with Pure Transplant Solutions allows us to develop unique approaches to study the unique involvement of HLA-DQ in transplant immunology."

"In the last years, we have seen a re-emerging role of HLA-DQ in transplantation medicine with increasing evidence that DQ mismatches between transplant recipient and donor are most detrimental to graft survival," said Dr. Buchli. "Our panel of highly representative HLA-DQ alleles will help to drive novel research to prevent transplant rejection and to contribute to more insight into DSA responses and we are thrilled to be working with Dr. Tambur, a world leader in this field."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: www.puretransplant.com

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, www.hlaprotein.com, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Alliances and Partnerships, Business, Drugs and Pharmaceuticals, Free News Articles, Surgery and Neurotechnology

Pure Transplant Solutions Announces Collaboration with the University of Alabama at Birmingham to Develop Memory B Cell-Directed Diagnostics for HLA-Sensitized Patients

BIRMINGHAM, Ala. -- Pure Transplant Solutions, LLC (PTS), a collaboration driven biotechnology company focused on the development of human leukocyte antigen (HLA)-based diagnostics and therapeutics within the field of transplantation, is proud to announce that it has entered into a collaboration agreement with The University of Alabama at Birmingham (UAB), a leading institution in transplant research, to develop a new class of transplant diagnostics aimed at the detection and identification of HLA-specific memory B cells which are poised to produce HLA-specific immunoglobulin injurious to transplanted grafts.

The research is being led by Dr. Frances Lund, Charles H. McCauley Professor and Chair Department of Microbiology, Dr. John Killian, resident in the Department of Surgery, and Dr. Rico Buchli, VP of Products and Services at PTS, and focuses on using PTS's newly created Class I and Class II biotinylated soluble HLA (sHLA) proteins to understand the breadth and specificity of HLA-reactive B cells in sensitized individuals. These proprietary HLA molecules can be utilized in standard flow cytometry workflows for easy processing and analysis that the parties hope will provide a new tool for clinicians and researchers to use when caring for transplant patients.

Almost all previous work on HLA sensitized individuals has relied upon assays that detect circulating anti-HLA antibodies. The goal is to determine the reactivities of HLA-reactive B cells in these sensitized patients and compare these reactivities to those that are present among circulating anti-HLA antibodies. Using panels of biotinylated HLA molecules in combination with various tetramerized fluorescent reagents allows the interrogation of the specific B cell receptors expressed by HLA-reactive B cells.

"Prevention of B cell activation and proliferation is crucial for the survival of a transplant patient. For patient monitoring, identifying the right approach to immune profiling at each stage of clinical development-including the later stages, when it is often considered impractical to include these approaches-may be critical for identifying predictors of rejection responses, or monitoring immunosuppression efficacy", said Dr. Buchli. "Flow cytometric analysis using our fluorescent tagged HLA products have the capabilities needed to meet the increased demands to detect, identify, and monitor HLA-specific memory B cells."

"Our research at the University of Alabama at Birmingham seeks to improve the success of organ transplants," said John Killian, Jr., M.D., a research resident in the UAB Department of Surgery. "One problem is that following pregnancy or transplant, patients form antibodies against non-self HLA molecules. These antibodies comprise a major barrier to transplantation, and they exacerbate gender and racial disparities for thousands of people who await a life-saving transplant. Thus, we want to understand the breadth and specificity of HLA-reactive memory B cells in sensitized women. Pure Protein's extensive selection of recombinant HLA molecules will be integral to our projects, allowing us to pair fluorescence-activated cell sorting of HLA-reactive B cells with subsequent analysis of recombinant-antibody specificities. An improved understanding of the phenotype and specificity of HLA-reactive B cells will offer new opportunities to diagnose and treat HLA sensitization."

About Pure Transplant Solutions, LLC

Pure Transplant Solutions, LLC was founded in 1999 in order to leverage the leading research in HLA protein of parent company, Pure Protein, LLC, into solutions to address a growing list of needs in organ transplantation. Visit: www.puretransplant.com

About Pure Protein, LLC

Pure Protein, LLC is a biotechnology company funded and managed by Emergent Technologies, Inc. that is focused on the development and commercialization of proprietary technologies related to the human leukocyte antigen (HLA) system, formed and exclusively licensed from the University of Oklahoma. Pure Protein, in conjunction with its affiliates and subsidiaries, aims to bring novel therapies and diagnostic tools to patients across a wide range of application areas spanning from therapeutic development in the fields of oncology, autoimmunity, and infectious disease, to antibody mediated rejection in transplantation.

Through its new ecommerce website, http://www.hlaprotein.com/, Pure Protein now offers academic and commercial researchers the ability to purchase individual HLA reagents to detect, profile, and monitor allele-specific immune responses, as well as HLA peptide epitope binding services to aide in improving the design of vaccination and therapeutic targeting strategies.

About the University of Alabama Birmingham

Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham, a part of the University of Alabama System, is an internationally renowned research university and academic medical center with over $600 million in research awards annually, as well as Alabama's largest employer, with some 23,000 employees, and has an annual economic impact exceeding $7 billion on the state. The pillars of UAB's mission include education, research, innovation and economic development, community engagement, and patient care. Learn more at https://www.uab.edu/.

Related link: https://www.puretransplant.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Defense and Military, Free News Articles, Surgery and Neurotechnology

‘Special Twins’ Tour of Duty Makes History

HOWELL, N.J. -- Mid-Atlantic Multi-Specialty Surgical Group, L.L.C. (MAMSURG) is announcing that two of their providers, Vince and Vance Moss, Army Reservists, Colonels, and G.H.O.S.T. surgeons for U.S. Special Operations Command, are returning home from Afghanistan in support of Operation Resolute Support following a unique, unprecedented 6 month tour of duty, making history by serving with the special forces as forward trauma surgeons, side by side.

Family members serving simultaneously in combat is rare, but even more uncommon is twins serving together in the same combat theater with the U.S. Special Operations. This rarity has become a reality. Twin brothers, Colonels Vince and Vance Moss (49 years old) have served on active duty together with the 909th General Hour Offset Surgical Team (G.H.O.S.T.), U.S. Special Operations Command in Afghanistan since January 2020. This act alone has not been known to be done on record. They had the unique experience of providing trauma surgery for the special forces during their missions. While serving, Vince's wife gave birth to his son, making this homecoming even more special when he meets him for the first time.

"It's been unbelievable serving with Vance in combat with so many talented warriors. I think it allowed me, once and for all, the opportunity to show my baby brother who's the better surgeon. I'm certainly looking forward to getting home and meeting my son for the first time and sharing that experience with my brother," said Vince Moss.

"It's been a great experience serving with the special forces environment with my brother at my side. I can't truly put into words how to describe the many reactions we received when people saw us. It was quite extraordinary. I'm looking forward to meeting my nephew for the first time," said Vance Moss.

The twins are originally from the Washington D.C. area. Penn State and Temple graduates, they are in private practice in New Jersey. The Moss brothers have been in the Army Reserves for over 15 years and served multiple tours in Iraq and Afghanistan. They have received many accolades for their work including being named ABC World News Tonight "Person(s) of the Year" and multiple invites to the White House.

The Moss brothers are scheduled to be returning home tentatively on June 30, 2020.

For more information, visit: https://www.mamsurg.com/.

About MAMSURG, L.L.C.:

Based in Howell, New Jersey, MAMSURG, L.L.C. is a surgical group of board-certified surgeons skilled in a variety of specialized techniques from renal transplantation, general surgery, urology and thoracic surgery. More importantly, their dedication to providing top notch, large center quality of care to the communities of New Jersey and the military is at the top of their agenda. The practice was started by Vince and Vance Moss in 2005 which the goal of focusing on underprivileged populations. For more information, visit: https://www.mamsurg.com/.

*PHOTO link for media: https://www.Send2Press.com/300dpi/20-07070s2p-Moss-Bros-2020-300dpi.jpg
*Photo caption: Surgeons/Colonels Vince (left) and Vance (right) Moss in an undisclosed location in Afghanistan with US Special Operations.

Related link: https://www.mamsurg.com

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Education and Schools, Free News Articles, Surgery and Neurotechnology

Record Early Enrollment for Lower Extremity Fellows, Residents & Young Surgeon 3rd Annual Course

SAN DIEGO, Calif. -- Magnifi Group, Inc. and Bespa Global, LLC, co-organizers of the program, announced today that despite the change of date for its 3rd Annual Lower Extremity IEP Fellows, Residents and Young Surgeons Course it is still experiencing record early registration. The course, originally scheduled for May 1-3 will take place from November 6-8, 2020 at The Omni Downtown, Austin, Texas.

This increased level of interest has been attributed to COVID-19 and the lack of in-person training opportunities for these young clinicians.

Lower Extremity IEP Program Co-chair, Dr. Donald R. Bohay, who serves as Professor Orthopaedic Surgery, Michigan State University and the Director of Grand Rapids Orthopedic Foot and Ankle Fellowship Program, said now more than ever, the prior and incoming class of Orthopedic Fellows and Final Year Podiatric Residents will significantly benefit from the Lower Extremity IEP Course.

"Given the current pandemic, these residents and fellows have not had the opportunity to participate in the usual array of cases, cadaver labs and in-person educational sessions," Dr. Bohay said. Dr. Bohay added that the impact is not limited to large COVID-19 cluster cities - it has impacted centers and schools across the country.

The Lower Extremity IEP Fellows, Residents & Young Surgeons' Course has been specifically developed to educate Fellows, Residents and Young Surgeons on current topics related to the practice of foot and ankle surgery, as well as to assist attendees with the transition from academics to practicing surgeon. The classroom format for the course is highly interactive; all sessions conclude with question/answer sessions and panel discussions. The course will be limited to 35 attendees to accommodate a didactics rotation schedule of up to 15 tables hosted by medical device and biologics companies. Cadaver labs will also be offered during the intense 21/2 day course.

Dr. Christopher L. Reeves, Program Co-chair and Faculty and Director of Research Advent Health Podiatric Surgical Residency, said he anticipates registration will fill up by mid-September. "The registration process will pick up even faster once the outgoing group of fellows and residents know their schedules and the incoming group are firmly in place."

The Lower Extremity IEP Fellows, Residents & Young Surgeons' Course is led by Dr. Gregory C. Pomeroy, Clinical Associate Professor of Surgery at the University of New England.

Magnifi Group, Inc. is a developer of a FDA-compliant eLearning platform for the medical device and biologics industries. The company also hosts the Spine IEP Live Fellows Course; the Lower Extremity IEP Live Fellows Course and the Hip and Knee IEP Live Fellows Course.

Bespa Global, LLC is dedicated to improving patient care through education and advancements in medical science. Our unique model is changing the way Medical Companies and Health Care Professionals work together to improve patient outcomes.

Learn more at: https://www.lowerextremity-iep.com/

For Additional Information Contact:

Laura McClain: lmcclain@magnifigroup.com

Chris Newell: cnewell@bespaglobal.com

*IMAGE link for media: https://www.Send2Press.com/300dpi/20-0521s2p-seal-lower-iep-300dpi.jpg

Related link: http://www.magnifigroup.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Education and Schools, Free News Articles, Surgery and Neurotechnology

Record Early Spine Fellows & Young Surgeon Enrollment for 10th Annual November Spine IEP Course

SAN DIEGO, Calif. -- Magnifi Group, Inc., announced today it is experiencing record early registration for its 10th Annual Spine IEP Fellows & Young Surgeons' Course (Spine Interactive Educational Program). The course will be conducted November 20-22 at The Fairmont Hotel, Austin, Texas.

A significant number of US Spine Fellowship Directors attribute the stepped-up early registration due to COVID-19.

Spine IEP Faculty member, Dr. R. Todd Allen, who serves as Associate Clinical Professor of Orthopaedic Surgery and Spine Surgery at the University of California, San Diego (UCSD) and Director of the University's Spine Fellowship program, said, now more than ever, the incoming Spine and Neuro Fellowship class of 2020-2021 will significantly benefit from the Spine IEP Course.

"Given the current pandemic, final-year Orthopaedic residents looking ahead to their spine fellowships, have not had the opportunity to take full advantage of their final residency year when it comes to surgical electives - as they relate to didactic spine work, labs and clinical training," Dr. Allen said. Dr. Allen added that even those schools offering a Chief Resident Rotation have been impacted.

The Spine IEP Fellows & Young Surgeons' Course will be limited to 50 attendees to accommodate a didactics rotation schedule of 45 tables hosted by medical device and biologics companies. Four cadaver labs will also be offered during the intense 21/2 day course.

The Spine IEP has been specifically developed to educate spine and neurosurgery Fellows and Young Surgeons on current topics related to the practice of spine and neurosurgery, as well as to assist attendees with the transition from academics to practicing surgeon. The classroom format for the course is highly interactive; all sessions conclude with question/answer sessions and panel discussions.

Laura McClain, Course Coordinator, said she anticipates registration fill up as early as July/August. "The upcoming course will represent the largest gathering ever of Spine Fellows and Young Surgeons for an educational event of this kind," McClain said. "Our sponsors also recognize that this course represents a significant opportunity to expose their latest techniques, products and treatments to the next-generation of spine and neuro surgeons," McClain added.

The Spine IEP Fellows & Young Surgeons' Course is led by Dr. Frank Phillips, Professor and Director, Division of Spine Surgery and Fellowship Co-Director, Spine Surgery at Rush University Medical Center, Chicago, Ill. To register: https://www.spine-iep.com/sfc/register.html

According to Magnifi data, an average of 70-80 spine Fellows enters the US market each year as practicing spine surgeons. Of these, 48-50 Fellows & Young Surgeons are expected to attend the upcoming course.

Magnifi Group, Inc. is a developer of an FDA-compliant eLearning platform for the medical device and biologics industries. The company also hosts the Spine IEP Live Fellows Course; the Lower Extremity IEP Live Fellows Course and the Hip and Knee IEP Live Fellows Course.

For Additional Information Contact:
Laura McClain: lmcclain@magnifigroup.com

Related link: http://www.magnifigroup.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Awards and Honors, Business, Free News Articles, Surgery and Neurotechnology

Charleston Oral and Facial Surgery Recognized as ‘Best of’ in Summerville and Mount Pleasant

CHARLESTON, S.C. -- Charleston Oral and Facial Surgery (COAFS) was voted a 2019 Reader's Choice recipient by the readers of "Journal Scene." Named Best Oral Surgeons in the annual Best of Summerville competition, COAFS will be featured in the 2019 Reader's Choice special edition. Winners in all categories were announced at a party held at The Village of Summerville on February 25, 2020.

In addition to accolades from Summerville, COAFS was recently named 2020 Best Oral Surgery Practice by Mount Pleasant Magazine. Nearly 50,000 votes were cast by magazine readers.

Led by a team of highly trained, board-certified oral surgeons - Dr. Edward R. Strauss, DMD, MD; Dr. Aaron P. Sarathy, DMD; Dr. A Drane Oliphant, DMD, MD; Dr. Graham Lee, DMD; and Dr. Scott H. Godwin, DMD - Charleston Oral and Facial Surgery has six convenient locations in the Lowcountry area, including Charleston, North Charleston, Summerville, Mount Pleasant, Bluffton and Knightsville.

Some of the practice's specialties include: total smile transformation, full-arch dental implants, implant-supported dentures, wisdom teeth extraction, same-day dental implants and corrective jaw surgery, to name just a few. Using advanced surgical techniques and state-of-the-art, cutting-edge technology, COAFS maintains a patient-centric philosophy to ensure that every client, regardless of the treatment, receives the ultimate patient experience.

"At COAFS, our surgeons are constantly striving to provide the highest quality care to our patients," said Dr. Aaron P. Sarathy, DMD. "We strive to give back to the community and to know our patients are recognizing this is a true honor for our doctors and team."

To learn more about COAFS, visit https://www.charlestonoralandfacialsurgery.com/.

For media inquiries, contact Stacey Kole with Branded Pros at 480.221.5818 or email stacey@brandedpros.com.

About Charleston Oral and Facial Surgery

COAFS has six locations in the Lowcountry, S.C. area, where its highly trained, board-certified surgeons provide patients with state-of-the-art treatment. With a commitment to cutting-edge technology and ongoing education, Charleston Oral and Facial Surgery offers the most advanced surgical techniques coupled with compassionate to produce the ultimate patient experience - every single time.

More information: https://www.charlestonoralandfacialsurgery.com/

Related link: https://www.charlestonoralandfacialsurgery.com/

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, Regional Events, Surgery and Neurotechnology

Fifteen Neurotechnology Startups to Present at the 2019 Neurotech Leaders Forum in San Francisco

SAN FRANCISCO, Calif. -- Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that 15 promising neurotechnology startups and early-stage firms will present at the 2019 Neurotech Leaders Forum in San Francisco, November 4-5. The 19th annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.

Josh Makower, general partner at VC firm New Enterprise Associates, will keynote on the first day of the conference. Makower is cofounder of the Stanford Byers Biodesign Center and also founder and executive chairman of ExploraMed, a medical device incubator that has created eight companies over the past 20 years.

Robert Knight, professor of psychology and neuroscience and director emeritus of the Helen Wills Neuroscience Institute at UC Berkeley, will deliver the keynote on the second day of the event. Knight is the recipient of the Jacob Javits Neuroscience Investigator Award from the National Institutes of Health for distinguished contributions to neurological research. He is also the chief science advisor of Neurofocus Inc., the consumer neurotech spinoff company acquired by market research firm Nielsen.

The agenda for this year's event includes panel discussions on a number of topics, including sessions devoted to clinical trials, securing funding, the new competitive landscape in neuromodulation, closed-loop stimulation, and neurorehabilitation. New this year is an editorial roundtable featuring Neurotech Reports editors James Cavuoto, Jennifer French, Jeremy Koff, and Margot Puerta, who will each offer their perspectives on issues confronting the industry.

Among the companies presenting this year are Saluda Medical, Nia Therapeutics, Neuroelectrics, Humm, Evoke Neuroscience, Neural Dynamics Technologies, Spark Biomedical, Thermaquil, Humm, Neuraura, CareWear, Rune Labs, Neural Signals, and BIOS.

The Platinum Sponsor at this year's event is Cirtec Medical. Micro Systems Technology is the Gold Sponsor. Maynard Cooper and Integer are Silver Sponsors, and RBrooks Group, Senso Medical, and the Cleveland FES Center are Bronze Sponsors.

"We're excited about the lineup of speakers at this year's event," said James Cavuoto, editor and publisher at Neurotech Reports. "As in the past, attendees will have many opportunities to interact with potential partners and colleagues."

For more information on attending or sponsoring, contact Neurotech Reports at 415 546 1259 or visit this link: http://neurotechreports.com/pages/leadersforum.html.

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, Private Practice and Medical Groups, Surgery and Neurotechnology

Surgery Center of Oklahoma Offers Procedure Financing Through MedPlan Credit

OKLAHOMA CITY, Okla. -- Surgery Center of Oklahoma now offers surgical procedure financing through their financing partner, MedPlan Credit of Tulsa.

Patients now have the opportunity to apply for financing, using MedPlan's technology platform, through a link on SCOK's website or through a form on Medplan's website. Applicants are assessed and receive an immediate credit decision, followed by automated verification steps for final approval and setup.

"At Surgery Center of Oklahoma, we believe that a different approach to health care delivery is necessary, one involving transparent and direct pricing," said Dr. Keith Smith, SCOK's CEO. "Transparent, direct, package pricing means the patient knows exactly what the cost of the service will be upfront. Patients who choose Surgery Center of Oklahoma and need to finance their procedure are directed to MedPlan's online financing application. MedPlan Credit is the best we have seen at providing an easy application process and a high percentage of approved applications."

MedPlan Credit is an online lending platform dedicated to creating an easy lending process for health care consumers. Through its robust and efficient digital platform, MedPlan makes the whole lending process fast and convenient.

About Surgery Center of Oklahoma:

The Surgery Center of Oklahoma is 32,535-square-foot, state-of-the-art multispecialty facility in Oklahoma City, owned and operated by approximately 40 of the top surgeons and anesthesiologists in central Oklahoma with 112 doctors on their surgical staff. SCOK's pricing for surgical procedures are a fraction of the prices charged at nonprofit hospitals. Since SCOK controls every aspect of the facility, they are able to eliminate wasteful operating room practices while providing the very best quality care to their patients. More information is available at https://surgerycenterok.com/.

About MedPlan Credit:

MedPlan Credit partners with health care providers to offer financing for high deductibles and other out-of-pocket costs. MedPlan loans allow patients to receive health care when they need it instead of waiting until they can afford it. MedPlan offers a quick and easy application/approval process with competitive, affordable interest rates. More information is available at https://www.medplancredit.com/

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.

Business, Free News Articles, Private Practice and Medical Groups, Surgery and Neurotechnology

New Advancement Allows for Septoplasty Procedure with Minimal Downtime

ATLANTA, Ga. -- Dr. Aaron Rogers and Advanced Ear Nose & Throat Associates, a leading Atlanta-based Otolaryngology medical practice, announces further advancement in office-based nasal surgery. New techniques allow for a full spectrum of corrective nasal surgery to now be done in the office with just minimal recovery.

The medical industry is constantly evolving with new techniques and technologies that improve the recovery process and results for patients. One of the newest advancements to hit the market is the development of an incisionless septoplasty that is minimally invasive and has a much faster recovery period than traditional septoplasty procedures. Dr. Aaron Rogers, based in the Metro Atlanta Area, has perfected this technique in order to help patients with nasal allergies, sinus infections and other nasal problems.

No-Scalpel septoplasty is a new procedure that is performed under local anesthesia utilizing the the Acclarent Relieva TRACT(R) device. The procedure utilizes pressurized inflatable dilators to remodel the nasal septal spurs and deflection that lead to nasal blockage. It takes just a few minutes, as opposed to traditional septoplasty procedures that require general anesthesia and are performed over the course of a few hours in an operating room.

The no-scalpel technique can be performed alongside other nasal procedures including balloon sinuplasty, turbinate reduction or nasal valve collapse repair. This procedure is recommended for adults who have nasal congestion or suffer from allergies, as well as patients who have had prior septoplasty but a residual spur.

One of the most attractive benefits of this treatment is the fast recovery period that lasts just a couple of days with mild discomfort and minimal bleeding. Patients can go to work the following day and costs are lower than traditional surgeries because anesthesiology and facility costs are avoided.

Dr. Rogers of Advanced Ear, Nose and Throat Associates is one of the first doctors in the Atlanta area to offer this new advanced technique. He has seen firsthand the increased benefits it provides to patients.

According to Dr. Rogers, "Treating deviated septum in the office is finally a practical reality, opening to doors to comfortable and comprehensive in-office nasal surgery."

More information: https://AdvancedENTpc.com/incisionless-septoplasty-with-dr-rogers/

VIDEO (YouTube): https://youtu.be/qts5WGeDrsg

Related link:

This news story was published by the Neotrope® News Network - all rights reserved.